A nomogram to predict the cancer-specific survival of stage II-IV Epithelial ovarian cancer after bulking surgery and chemotherapy
- PMID: 34057318
- PMCID: PMC8267121
- DOI: 10.1002/cam4.3980
A nomogram to predict the cancer-specific survival of stage II-IV Epithelial ovarian cancer after bulking surgery and chemotherapy
Abstract
Objective: In order to predict the survival rate of ovarian cancer patients, multiple independent risk factors are integrated to establish a prognostic nomogram.
Methods: Cox analysis was used to construct the nomogram. All of the mainly independent factors, which can be used to predict 3-year and 5-year survival rates for cancer in the training cohort, were incorporated to establish nomograms. The C-index, operating characteristic, ROC curves, and calibration plots can show evaluation results of performance.
Results: Model derivation was based on 3277 patients who belong to different races. The best threshold for age was 51, 59, and 67 year old and the older the people, the worse their survival. Meanwhile, many lymph node examinations indicated a favorable survival and the survival of the positive set was worse than of that. In addition, the optional threshold was 64 mm for tumor size and the set larger than 64 mm had a better survival than that less than 64 mm. Univariate Cox proportional hazards regression model showed that the similar worse outcomes were showed in black race, advanced grade, stage T3, stage M1, lymph nodes positive, and CA125 positive compared with the first group. We found that the number of lymph nodes examined and tumor size had an inverse relationship with its corresponding score of CSS in training cases with bulking surgery and chemotherapy.
Conclusions: We developed a model which relatively accurately predicted the prognosis of ovarian cancer by multiple univariate analysis, at the same time, the proposed nomograms exhibit superior prognostic discrimination and survival prediction.
Keywords: SEER; nomogram; ovarian cancer; prognosis; surgical therapy; survival.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors have no conflict of interest to declare.
Figures
Similar articles
-
A prognostic model of patients with ovarian mucinous adenocarcinoma: a population-based analysis.J Ovarian Res. 2022 Feb 16;15(1):26. doi: 10.1186/s13048-022-00958-6. J Ovarian Res. 2022. PMID: 35168642 Free PMC article.
-
A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer.Oncotarget. 2017 Jan 31;8(5):8120-8130. doi: 10.18632/oncotarget.14100. Oncotarget. 2017. PMID: 28042955 Free PMC article.
-
Nomograms predicting the overall survival and cancer-specific survival of patients with stage IIIC1 cervical cancer.BMC Cancer. 2021 Apr 23;21(1):450. doi: 10.1186/s12885-021-08209-5. BMC Cancer. 2021. PMID: 33892663 Free PMC article.
-
Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study.BMC Cancer. 2021 May 25;21(1):609. doi: 10.1186/s12885-021-07977-4. BMC Cancer. 2021. PMID: 34034697 Free PMC article.
-
[Surgery in early-stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].Gynecol Obstet Fertil Senol. 2019 Feb;47(2):168-179. doi: 10.1016/j.gofs.2018.12.007. Epub 2019 Jan 25. Gynecol Obstet Fertil Senol. 2019. PMID: 30686727 Review. French.
Cited by
-
Differences of survival benefits brought by various treatments in ovarian cancer patients with different tumor stages.J Ovarian Res. 2023 May 11;16(1):92. doi: 10.1186/s13048-023-01173-7. J Ovarian Res. 2023. PMID: 37170143 Free PMC article.
-
Prediction for 2-year mortality of metastatic ovarian cancer patients based on surveillance, epidemiology, and end results database.Front Surg. 2022 Sep 15;9:974536. doi: 10.3389/fsurg.2022.974536. eCollection 2022. Front Surg. 2022. PMID: 36338661 Free PMC article.
-
Conditional Survival of Advanced Epithelial Ovarian Cancer: A Real-World Data Retrospective Cohort Study From the SEER Database.Front Med (Lausanne). 2021 Nov 23;8:756401. doi: 10.3389/fmed.2021.756401. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34888325 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7‐34. - PubMed
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424. - PubMed
-
- Vogel TJ, Jeon C, Karlan B, Walsh C. Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: a SEER‐Medicare database analysis. Gynecol Oncol. 2016;140(2):285‐288. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
